Kancera AB (publ)

SSE:KAN.ST

4.09 (SEK) • At close February 20, 2024
Bedrijfsnaam Kancera AB (publ)
Symbool KAN.ST
Munteenheid SEK
Prijs 4.095
Beurswaarde 333,766,251
Dividendpercentage 0%
52-weken bereik 2.22 - 6.77
Industrie Biotechnology
Sector Healthcare
CEO Dr. Thomas Olin Ph.D.
Website https://www.kancera.com

An error occurred while fetching data.

Over Kancera AB (publ)

Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to

Vergelijkbare Aandelen

Guard Therapeutics International AB (publ) logo

Guard Therapeutics International AB (publ)

GUARD.ST

19.8 SEK

Alligator Bioscience AB (publ) logo

Alligator Bioscience AB (publ)

ATORX.ST

1.178 SEK

I-Tech AB logo

I-Tech AB

ITECH.ST

39.7 SEK

Initiator Pharma A/S logo

Initiator Pharma A/S

INIT.ST

8.08 SEK

OssDsign AB (publ) logo

OssDsign AB (publ)

OSSD.ST

8.8 SEK

Dignitana AB (publ) logo

Dignitana AB (publ)

DIGN.ST

1.94 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)